BioCentury
ARTICLE | Clinical News

Ibrutinib: Preliminary Phase II data

December 17, 2012 8:00 AM UTC

Preliminary data from an open-label Phase II trial in 70 patients with either activated B cell (ABC) subtype or germinal center ( GC) subtype DLBCL showed that once-daily 560 mg oral ibrutinib produce...